These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37815775)
1. Differential response of mesenchymal stromal cells (MSCs) to type 1 ex vivo cytokine priming: implications for MSC therapy. Burnham AJ; Foppiani EM; Goss KL; Jang-Milligan F; Kamalakar A; Bradley H; Goudy SL; Trochez CM; Dominici M; Daley-Bauer L; Gibson G; Horwitz EM Cytotherapy; 2023 Dec; 25(12):1277-1284. PubMed ID: 37815775 [TBL] [Abstract][Full Text] [Related]
2. Unveiling the functional heterogeneity of cytokine-primed human umbilical cord mesenchymal stem cells through single-cell RNA sequencing. Hu Z; Li D; Wu S; Pei K; Fu Z; Yang Y; Huang Y; Yang J; Liu C; Hu J; Cai C; Liao Y Cell Biosci; 2024 Mar; 14(1):40. PubMed ID: 38532459 [TBL] [Abstract][Full Text] [Related]
3. Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Cui R; Rekasi H; Hepner-Schefczyk M; Fessmann K; Petri RM; Bruderek K; Brandau S; Jäger M; Flohé SB Stem Cell Res Ther; 2016 Jul; 7(1):88. PubMed ID: 27388156 [TBL] [Abstract][Full Text] [Related]
4. Human Wharton's Jelly-Derived Mesenchymal Stromal Cells Primed by Tumor Necrosis Factor-α and Interferon-γ Modulate the Innate and Adaptive Immune Cells of Type 1 Diabetic Patients. Mrahleh MA; Matar S; Jafar H; Wehaibi S; Aslam N; Awidi A Front Immunol; 2021; 12():732549. PubMed ID: 34650558 [TBL] [Abstract][Full Text] [Related]
5. Priming Mesenchymal Stem/Stromal Cells with a Combination of a Low Dose of IFN-γ and Bortezomib Results in Potent Suppression of Pathogenic Th17 Immunity Through the IDO1-AHR Axis. Park HY; Kim CE; Lee SM; Ahn JM; Yoon EH; Yoo M; Kim JM; Back J; Park DH; Jang WH; Kwon B; Seo SK Stem Cells; 2023 Jan; 41(1):64-76. PubMed ID: 36242771 [TBL] [Abstract][Full Text] [Related]
6. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment. Cassano JM; Schnabel LV; Goodale MB; Fortier LA Stem Cell Res Ther; 2018 Apr; 9(1):82. PubMed ID: 29615127 [TBL] [Abstract][Full Text] [Related]
7. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. Saldaña L; Bensiamar F; Vallés G; Mancebo FJ; García-Rey E; Vilaboa N Stem Cell Res Ther; 2019 Feb; 10(1):58. PubMed ID: 30760316 [TBL] [Abstract][Full Text] [Related]
8. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation. Cuerquis J; Romieu-Mourez R; François M; Routy JP; Young YK; Zhao J; Eliopoulos N Cytotherapy; 2014 Feb; 16(2):191-202. PubMed ID: 24438900 [TBL] [Abstract][Full Text] [Related]
9. Effect of pro-inflammatory cytokine priming and storage temperature of the mesenchymal stromal cell (MSC) secretome on equine articular chondrocytes. Jammes M; Contentin R; Audigié F; Cassé F; Galéra P Front Bioeng Biotechnol; 2023; 11():1204737. PubMed ID: 37720315 [No Abstract] [Full Text] [Related]
10. Regulatory-compliant conditions during cell product manufacturing enhance in vitro immunomodulatory properties of infrapatellar fat pad-derived mesenchymal stem/stromal cells. Kouroupis D; Bowles AC; Greif DN; Leñero C; Best TM; Kaplan LD; Correa D Cytotherapy; 2020 Nov; 22(11):677-689. PubMed ID: 32723596 [TBL] [Abstract][Full Text] [Related]
11. In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter. Rovira Gonzalez YI; Lynch PJ; Thompson EE; Stultz BG; Hursh DA Cytotherapy; 2016 Sep; 18(9):1114-28. PubMed ID: 27421739 [TBL] [Abstract][Full Text] [Related]
12. GVHD-derived plasma as a priming strategy of mesenchymal stem cells. Silva-Carvalho AÉ; Rodrigues LP; Schiavinato JL; Alborghetti MR; Bettarello G; Simões BP; Neves FAR; Panepucci RA; de Carvalho JL; Saldanha-Araujo F Stem Cell Res Ther; 2020 Apr; 11(1):156. PubMed ID: 32299501 [TBL] [Abstract][Full Text] [Related]
13. Preconditioning of bone marrow-derived mesenchymal stem cells highly strengthens their potential to promote IL-6-dependent M2b polarization. Philipp D; Suhr L; Wahlers T; Choi YH; Paunel-Görgülü A Stem Cell Res Ther; 2018 Oct; 9(1):286. PubMed ID: 30359316 [TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. Hemeda H; Jakob M; Ludwig AK; Giebel B; Lang S; Brandau S Stem Cells Dev; 2010 May; 19(5):693-706. PubMed ID: 20067407 [TBL] [Abstract][Full Text] [Related]
16. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. Prasanna SJ; Gopalakrishnan D; Shankar SR; Vasandan AB PLoS One; 2010 Feb; 5(2):e9016. PubMed ID: 20126406 [TBL] [Abstract][Full Text] [Related]
17. Changes in the secretome of tri-dimensional spheroid-cultured human mesenchymal stem cells in vitro by interleukin-1 priming. Redondo-Castro E; Cunningham CJ; Miller J; Brown H; Allan SM; Pinteaux E Stem Cell Res Ther; 2018 Jan; 9(1):11. PubMed ID: 29343288 [TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effect of human bone marrow-derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients. Pedrosa M; Gomes J; Laranjeira P; Duarte C; Pedreiro S; Antunes B; Ribeiro T; Santos F; Martinho A; Fardilha M; Domingues MR; Abecasis M; P da Silva JA; Paiva A J Tissue Eng Regen Med; 2020 Jan; 14(1):16-28. PubMed ID: 31502378 [TBL] [Abstract][Full Text] [Related]